Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2011 1
2012 3
2013 4
2014 9
2015 16
2016 18
2017 16
2018 18
2019 14
2020 23
2021 37
2022 32
2023 24
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

194 results

Results by year

Filters applied: . Clear all
Page 1
Molecular biology of cholangiocarcinoma and its implications for targeted therapy in patient management.
Gilbert TM, Randle L, Quinn M, McGreevy O, O'leary L, Young R, Diaz-Neito R, Jones RP, Greenhalf B, Goldring C, Fenwick S, Malik H, Palmer DH. Gilbert TM, et al. Eur J Surg Oncol. 2024 Apr 17:108352. doi: 10.1016/j.ejso.2024.108352. Online ahead of print. Eur J Surg Oncol. 2024. PMID: 38653586
Currently, 3 targeted therapies are approved for use in CCA; Ivosidenib in patients with IDH1 mutations and Infigratinib/Pemigatinib in those with FGFR2 fusions. As our understanding of the biology underpinning CCA continues to improve it is highly likely that additional t …
Currently, 3 targeted therapies are approved for use in CCA; Ivosidenib in patients with IDH1 mutations and Infigratinib/Pemigatinib …
Low-Dose Infigratinib Increases Bone Growth And Corrects Growth Plate Abnormalities In An Achondroplasia Mouse Model.
Demuynck B, Flipo J, Kaci N, Dambkowski C, Paull M, Muslimova E, Shah BP, Legeai-Mallet L. Demuynck B, et al. J Bone Miner Res. 2024 Apr 9:zjae051. doi: 10.1093/jbmr/zjae051. Online ahead of print. J Bone Miner Res. 2024. PMID: 38590263
In this study, we investigated the activity of infigratinib administered at substantially lower doses (0.2 and 0.5 mg/kg, given once daily) and using an intermittent dosing regimen (1 mg/kg every 3 days). ...Immunohistological labeling demonstrated the positive impact of …
In this study, we investigated the activity of infigratinib administered at substantially lower doses (0.2 and 0.5 mg/kg, given once …
Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial.
Pal SK, Grivas P, Gupta S, Dizman N, Zengin Z, Valderrama BP, Rodriguez-Vida A, Roghmann F, Sevillano Fernandez E, Matin SF, Loriot Y, Sridhar SS, Sonpavde G, Fleming MT, Lerner SP, Bellmunt J, Master V, Tripathi A, Davis K, van Veenhuyzen D, Weng R, Daneshmand S. Pal SK, et al. Eur Urol. 2024 Apr 4:S0302-2838(24)02247-4. doi: 10.1016/j.eururo.2024.03.023. Online ahead of print. Eur Urol. 2024. PMID: 38580518 No abstract available.
Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma.
Matin SF, Adibi M, Shah AY, Alhalabi O, Corn P, Guo C, Amirtharaj R, Xiao L, Lange S, Duose DY, Wang S, Pal S, Campbell MT. Matin SF, et al. J Urol. 2024 Apr 10:101097JU0000000000003928. doi: 10.1097/JU.0000000000003928. Online ahead of print. J Urol. 2024. PMID: 38573872
MATERIALS AND METHODS: Patients with localized UTUC undergoing ureteroscopy or nephroureterectomy/ureterectomy were enrolled on a phase 1b trial (NCT04228042). Once-daily infigratinib 125 mg by mouth 21 days (28-day cycle) was given for 2 cycles. ...RESULTS: From May 2021 …
MATERIALS AND METHODS: Patients with localized UTUC undergoing ureteroscopy or nephroureterectomy/ureterectomy were enrolled on a phase 1b t …
A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality.
Jain NK, Tailang M, Thangavel N, Makeen HA, Albratty M, Najmi A, Alhazmi HA, Zoghebi K, Alagusundaram M, Jain HK, Chandrasekaran B. Jain NK, et al. Acta Pharm. 2024 Mar 30;74(1):1-36. doi: 10.2478/acph-2024-0005. Print 2024 Mar 1. Acta Pharm. 2024. PMID: 38554385 Free article. Review.
FDA has approved four anticancer agents such as erdafitinib, pemigatinib, infigratinib, and futibatinib, for clinical use in oncogenic FGFR-driven malignancies. ...
FDA has approved four anticancer agents such as erdafitinib, pemigatinib, infigratinib, and futibatinib, for clinical use in oncogeni …
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions.
Katoh M, Loriot Y, Brandi G, Tavolari S, Wainberg ZA, Katoh M. Katoh M, et al. Nat Rev Clin Oncol. 2024 Apr;21(4):312-329. doi: 10.1038/s41571-024-00869-z. Epub 2024 Feb 29. Nat Rev Clin Oncol. 2024. PMID: 38424198 Review.
Various agents, including pan-FGFR inhibitors (erdafitinib and futibatinib), FGFR1/2/3 inhibitors (infigratinib and pemigatinib), as well as a range of more-specific agents, have been developed and several have entered clinical use. ...
Various agents, including pan-FGFR inhibitors (erdafitinib and futibatinib), FGFR1/2/3 inhibitors (infigratinib and pemigatinib), as …
Larotrectinib versus infigratinib for adult patients with both glioma and tyrosine kinase alterations after failure of initial therapies: Efficacy and safety analysis.
Chen Y, Ma J, Gao Q, Gai Y, Sun Y, Wang M. Chen Y, et al. Clinics (Sao Paulo). 2024 Feb 7;79:100329. doi: 10.1016/j.clinsp.2024.100329. eCollection 2024. Clinics (Sao Paulo). 2024. PMID: 38330791 Free PMC article.
OBJECTIVES: To compare the efficacy and safety of larotrectinib with those of infigratinib in adult glioma patients with tyrosine kinase alterations. METHODS: Patients received oral infigratinib 125 mg (IN cohort, n = 125) or oral larotrectinib (LB cohort, n = 105) …
OBJECTIVES: To compare the efficacy and safety of larotrectinib with those of infigratinib in adult glioma patients with tyrosine kin …
An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021).
S V, N N, Kurmi BD, Das Gupta G, Verma SK, Jain A, Patel P. S V, et al. Anticancer Agents Med Chem. 2024 Jan 29. doi: 10.2174/0118715206259585240105051941. Online ahead of print. Anticancer Agents Med Chem. 2024. PMID: 38288815
In this review, we report the compilation and analysis of a total of 56 drugs including 33 organic small molecules (Mobocertinib, Infigratinib, Sotorasib, Trilaciclib, Umbralisib, Tepotinib, Relugolix, Pralsetinib, Decitabine, Ripretinib, Selpercatinib, Capmatinib, Pemigat …
In this review, we report the compilation and analysis of a total of 56 drugs including 33 organic small molecules (Mobocertinib, Infigra …
Dual-Hit Strategy for Therapeutic Targeting of Pancreatic Cancer in Patient-Derived Xenograft Tumors.
Roy Chaudhuri T, Lin Q, Stachowiak EK, Rosario SR, Spernyak JA, Ma WW, Stachowiak MK, Greene MK, Quinn GP, McDade SS, Clynes M, Scott CJ, Straubinger RM. Roy Chaudhuri T, et al. Clin Cancer Res. 2024 Apr 1;30(7):1367-1381. doi: 10.1158/1078-0432.CCR-23-0131. Clin Cancer Res. 2024. PMID: 38270582
SHHi-treated tumors showed elevated FGF drive and distinctly higher nuclear localization of fibroblast growth factor receptor (FGFR1) in EMT-polarized tumor cells. Pan-FGFR inhibitor NVP-BGJ398 (Infigratinib) reversed the SHHi-induced EMT marker expression and nuclear FGFR …
SHHi-treated tumors showed elevated FGF drive and distinctly higher nuclear localization of fibroblast growth factor receptor (FGFR1) in EMT …
Infigratinib.
[No authors listed] [No authors listed] 2024 Jan 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2024 Jan 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 34554663 Free Books & Documents. Review.
Infigratinib is no longer marketed in the US. No information is available on the clinical use of infigratinib during breastfeeding. Because infigratinib is 96.8% bound to plasma proteins, the amount in milk is likely to be low. ...
Infigratinib is no longer marketed in the US. No information is available on the clinical use of infigratinib during breastfee …
194 results